Relmada Therapeutics, Inc.
NASDAQ:RLMD
3.09 (USD) • At close September 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.005 | 0.008 |
| Cost of Revenue
| 0 | 0 | 0.001 | 0.004 | 0 | 0.005 | 0.003 | 0.085 | 0.055 | 0.009 | 0.004 | 0.006 |
| Gross Profit
| 0 | 0 | -0.001 | -0.004 | 0 | -0.005 | -0.003 | -0.085 | -0.055 | -0.009 | 0.001 | 0.002 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.213 | 0.27 |
| Reseach & Development Expenses
| 54.807 | 113.323 | 90.622 | 35.973 | 7.859 | 7.025 | 2.943 | 1.293 | 6.207 | 7.872 | 5.38 | 0 |
| General & Administrative Expenses
| 48.895 | 47.926 | 35.082 | 24.866 | 7.25 | 5.703 | 3.975 | 5.925 | 10.009 | 9.227 | 0.045 | 0.009 |
| Selling & Marketing Expenses
| 12.308 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.001 | 0.005 |
| SG&A
| 48.895 | 47.926 | 35.082 | 24.866 | 7.25 | 5.703 | 3.975 | 5.925 | 10.009 | 9.227 | 0.046 | 0.014 |
| Other Expenses
| 0 | 6.352 | 0 | 0 | 0 | 0 | 0.002 | 0.216 | 0.13 | 0 | 0 | 0 |
| Operating Expenses
| 103.702 | 161.249 | 125.703 | 60.839 | 15.109 | 12.728 | 6.917 | 7.219 | 16.216 | 17.099 | 0.046 | 0.014 |
| Operating Income
| -103.702 | -161.249 | -125.703 | -60.839 | -15.109 | -12.728 | -6.917 | -7.219 | -16.216 | -17.099 | -0.045 | -0.012 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -8.777 | -1.518 |
| Total Other Income Expenses Net
| 4.911 | 1.546 | -1.247 | -0.017 | 0.104 | -3.829 | -0.707 | 0.933 | 13.239 | -3.71 | -9.584 | -0 |
| Income Before Tax
| -98.792 | -157.044 | -125.752 | -59.456 | -15.005 | -17.318 | -8.961 | -6.287 | -2.975 | -20.804 | -0.045 | -0.012 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -8.777 | -1.518 |
| Income Tax Expense
| -0.104 | -2.659 | 0.048 | -1.382 | -0 | 4.59 | 2.046 | -0.716 | -13.111 | 3.704 | -9.584 | -0 |
| Net Income
| -98.792 | -157.044 | -125.752 | -59.456 | -15.005 | -17.318 | -8.961 | -6.287 | -2.975 | -20.804 | -0.045 | -0.012 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -8.777 | -1.518 |
| EPS
| -3.28 | -5.3 | -7.16 | -3.81 | -1.63 | -2.74 | -2.86 | -2.08 | -1.03 | -8.37 | -0.032 | -0.009 |
| EPS Diluted
| -3.28 | -5.3 | -7.16 | -3.81 | -1.63 | -2.74 | -2.86 | -2.08 | -1.03 | -8.37 | -0.032 | -0.009 |
| EBITDA
| -103.702 | -156.443 | -124.455 | -60.818 | -15.105 | -8.894 | -6.206 | -7.85 | -29.27 | -13.38 | -0.045 | -0.011 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -8.728 | -1.423 |